Pfizer Inc. (PFE) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription dru...
Pfizer Inc. (PFE) currently trades at a P/E ratio of 21.35 (historical range: 12.36–40.46, median: 17.60), placing it at the 72th percentile — above its historical average, P/S ratio of 2.53 (range: 1.97–3.08, 85th percentile — expensive relative to its history), EV/EBITDA of 66.65 (range: 19.96–70.41, 93th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Pfizer Inc.'s P/E ratio has contracted by 36% over the observed period (from an average of 26.4 to 16.9).
Pfizer Inc. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 21.35 | 12.36 | 17.60 | 40.46 | 72th | above its historical average |
| P/S Ratio | 2.53 | 1.97 | 2.35 | 3.08 | 85th | expensive relative to its history |
| EV/EBITDA | 66.65 | 19.96 | 31.34 | 70.41 | 93th | expensive relative to its history |
| FCF Yield | 0.01 | 0.00 | 0.02 | 0.07 | 25th | above its historical average |